A placebo-controlled study to evaluate the effects of AR1001 in participants with early AD(more advanced patients with mild to moderate AD).

To be eligible for this study, a potential participant must:

Be between the ages of 55 and 90
Have noticed a change in your memory for the at least 3 years.
Study partner during the study
Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease/ Mild Cognitive Impairment.